精神分裂症的临床基因检测:系统综述与荟萃分析
该系统综述与荟萃分析检索2007年1月至2023年6月MEDLINE、Embase和APA PsycINFO,纳入31项研究共20476名精神分裂症个体,发现约6%(95%CI 4%至7%)检出临床显著遗传变异;染色体微阵列、外显子组测序和基因组测序的检出率分别为6%、5%和7%,研究间异质性高(I2=95.9%),且缺乏拉丁美洲、南亚和非洲的研究数据。
要点
- 精神分裂症个体临床显著遗传变异合并检出率约6%。
- 染色体微阵列检出率6%,外显子组测序5%,基因组测序7%。
- 研究间异质性高(I2=95.9%),地理代表性有限。
核心结论
- 基因检测在约6%的精神分裂症个体中识别出有临床信息的变异。
- 研究间存在显著异质性且地理代表性有限,需更标准化的检测方法和更广泛的人群采样。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和APA PsycINFO(2007年1月至2023年6月)。
- 纳入31项报告精神分裂症临床基因检测结果的研究,共20476名参与者。
- 两名独立评审者按PRISMA指南进行筛选、全文审查和数据提取,采用随机效应模型估计合并及平台特异性比例,用I2统计量评估异质性。
主要发现
- 31项研究共20476名参与者中,6%(95%CI 4%至7%)的精神分裂症个体检出临床显著遗传变异。
- 染色体微阵列检出率为6%(95%CI 4%至8%)。
- 外显子组测序检出率为5%(95%CI -0.02%至12%)。
- 基因组测序检出率为7%(95%CI 2%至12%)。
- 研究间异质性显著(I2=95.9%),且无来自拉丁美洲、南亚或非洲的研究。
关键数值与推荐
- 合并检出率:6%(95%CI 4%至7%),对象为精神分裂症个体。
- 染色体微阵列检出率:6%(95%CI 4%至8%)。
- 外显子组测序检出率:5%(95%CI -0.02%至12%)。
- 基因组测序检出率:7%(95%CI 2%至12%)。
- 异质性:I2=95.9%。
临床怎么用
- 临床可参考约6%的检出率向精神分裂症个体说明基因检测的阳性发现概率。
- 不同检测平台的检出率存在差异,选择平台时可结合可及性与检测目的。
- 结果解读需考虑研究间高异质性和地理代表性有限对推广性的影响。
局限性
- 研究间异质性显著(I2=95.9%)。
- 地理代表性有限,无来自拉丁美洲、南亚或非洲的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic testing may provide important diagnostic information for individuals with schizophrenia, but the frequency with which clinically significant variants are identified across different testing approaches has not been systematically evaluated. METHODS: We conducted a systematic review and meta-analysis searching MEDLINE, Embase, and APA PsycINFO (January 2007-June 2023) for studies reporting results of clinical genetic testing in schizophrenia. Two independent reviewers performed abstract/title screening, full-text review, and data extraction following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A random-effects model was used to estimate the pooled and platform-specific proportions of individuals with pathogenic or likely pathogenic variants, with heterogeneity assessed using the I2 statistic. RESULTS: Analysis of 31 studies (20,476 participants) showed that 6% (95% CI, 4% to 7%) of individuals with schizophrenia had a clinically significant genetic variant identified. Detection rates were 6% (95% CI, 4% to 8%) for chromosomal microarray, 5% (95% CI, -0.02% to 12%) for exome sequencing, and 7% (95% CI, 2% to 12%) for genome sequencing. Substantial heterogeneity was observed across studies (I2 = 95.9%). Geographic representation was limited, with no studies from Latin America, South Asia, or Africa. CONCLUSIONS: Genetic testing identifies clinically informative variants in approximately 6% of individuals with schizophrenia. However, substantial heterogeneity across studies and limited geographic representation underscore the need for more standardized testing approaches and broader population sampling in future genetic research on schizophrenia.
引用
- Brah HS, Sran N, Sanghani S, et al. Clinical Genetic Testing in Schizophrenia: A Systematic Review and Meta-Analysis. Biol Psychiatry. 2025. PMID: 41038604. doi:10.1016/j.biopsych.2025.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。